#Breaking The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted for a trivalent vaccine composition for use in the US, protecting against influenza A (H1N1 and H3N2) and influenza B (Victoria lineage).
www.contagionlive.com/view/fda-vrb...
Tapering vancomycin over 2 weeks after a 2-week full dose regimen for Clostridioides difficile reduced the rate of infection recurrence. #IDsky #Medsky
An increase in cases of blastomycosis in upstate New York over the past decade suggests it is becoming endemic, although not yet a reportable infection.
Peptilogics has enrolled the first patient in its RETAIN trial evaluating PLG0206, a first-in-class anti-biofilm therapy designed to treat prosthetic joint infections.
In this episode of our vaccine roundtable, our panel discuss how the pediatric immunization schedule changes could potentially influence vaccines inequities, and how vaccine education continues to play a significant role in immunization uptake and improving health equity.
A phase 2 trial published in The Lancet Infectious Diseases found that the investigational antibiotic CRS3123 achieved high clinical cure rates comparable to vancomycin while significantly reducing recurrence and preserving the gut microbiome in patients with Clostridioides difficile infection.
#ICYMI Our latest @sidpharm.bsky.social Bench to Bedside column is out! Authors discuss phage–antibiotic combinations that may benefit select patients with multidrug-resistant infections.
Read it here: www.contagionlive.com/view/phage-a...
In this episode, the panel discusses the continued importance of getting all children vaccinated and the potential unintended clinical care consequences of less individuals getting immunized if the current trends continue.
www.contagionlive.com/view/the-evo...
In the latest @sidpharm.bsky.social Bench to Bedside column, authors @aelghali.bsky.social and @danaholger.bsky.social discuss phage-antibiotic combinations that may benefit select patients with multidrug-resistant infections.
Rate of HBV vaccination of newborns in the US has declined by over 10 percent in the last 2 years, reversing decades of increasing coverage. #hepatitis
This week, read about the latest measles numbers, a risk assessment and antibiotic treatment of GAS pharyngitis, an analysis of ceftolozane-tazobactam over aminoglycosides/polymyxins for resistant P aeruginosa, and more.
#BREAKING The latest CDC numbers show a 12.76% increase of measles cases from week-to-week. This is a slight decrease in the number of cases from last week where there was a 15.7% increase. The data also shows outbreaks in 3 new states. #IDsky #Medsky
Despite increased risk for severe outcomes, most older adults and those with comorbidities do not receive antiviral treatment for COVID-19. #IDsky #Medsky
Despite the absence of vaccine data to support making changes, the ACIP continues to alter the pediatric schedule that will see less children getting immunized against vaccine-preventable diseases. In our continuing roundtable, our panel weighs in on this topic. #IDsky #Medsky
In 2025, the @idsainfo.bsky.social published the first part of an update to the clinical practice guideline on the diagnosis and management of GAS pharyngitis. Here is an overview of the risk assessment and antibiotic treatment of GAS pharyngitis. #IDsky #Medsky
#ICYMI Check out our roundtable, Clinical Insights: Childhood Vaccine Schedule Changes. This series discusses the ACIP’s new recommendations around pediatric vaccines.
Watch the first 2 episodes here: www.contagionlive.com/roundtables/...
Gilead’s One2PrEP campaign uses music, mainstream media, and bold visibility to normalize conversations about HIV prevention and expand awareness of evolving PrEP options.
#IDsky #Medsky
As the US continues to undergo policy changes to the pediatric childhood vaccine schedule, clinicians and families are left uncertain on recommendations and guidance. Our roundtable looks to provide some insights and answer questions to some of the more pressing topics around this evolving issue.
Moderna has cleared a major regulatory milestone in Europe after the EMA’s CHMP recommended approval of mRNA-1083 (mCOMBRIAX), the world’s first combined influenza and COVID-19 vaccine for adults aged 50 and older.
A modeling analysis shows the potential increases in cases, hospitalizations, deaths, as well as the healthcare costs associated with declining vaccination rates. Patricia Stinchfield, RN, MS, CPNP, discusses the measles outbreaks, strategies to increase vaccination. @nfidvaccines.bsky.social
Ceftolozane-tazobactam cure rate for multidrug-resistant Pseudomonas aeruginosa infections is higher than with aminoglycosides-polymyxins and comparable to ceftazidime-avibactam. #IDsky #Medsky
Patricia Stinchfield, RN, MS, CPNP, discusses her medical experience caring for patients with #measles, and what fellow clinicians and the general public should know about less-discussed details and potential complications. @nfidvaccines.bsky.social
#Breaking The latest CDC numbers show a 15.7% increase of measles cases from week-to-week. This is another large jump in cases, especially from last week where there was a 7.8% increase. The data also shows further outbreak spread across more states.
Eric Meissner, MD PhD, discusses the takeaways of the ARTISTRY-2, phase 3 study, which compared bictegravir/emtricitabine/tenofovir alafenamide to bictegravir/lenacapavir in adults with HIV who were virologically suppressed. #CROI2026
Phase 1 data show that the long-acting HIV-1 capsid inhibitor VH-499 is well tolerated as a single intramuscular or subcutaneous injection and demonstrates pharmacokinetics supportive of long-acting dosing intervals. #CROI2026
www.contagionlive.com/view/long-ac...
Dr. Chloe Orkin discusses the takeaways of the ARTISTRY-1 phase 3 study, including its efficacy and safety profile and the potential benefits of a single-tablet regimen in this patient population. #CROI2026
www.contagionlive.com/view/switchi...
New in vitro data presented at CROI show that Atea Pharmaceuticals’ oral nucleotide analog AT-587 demonstrates markedly superior potency against hepatitis E virus compared with existing off-label options, supporting plans to advance the candidate into phase 1 clinical development in 2026. #CROI2026
Amy Colson MD, MPH, discusses data from the MK8591A-052 trial which showed that switching to doravirine/islatravir maintained durable virologic suppression with efficacy and safety comparable to continuing bictegravir/emtricitabine/tenofovir alafenamide. #CROI2026
New 96-week sub-group data from the PASO DOBLE study show that adults with virologically suppressed HIV who switched to Dovato experienced significantly lower rates of steatotic liver disease than those who switched to Biktarvy, particularly among individuals with weight gain. #croi2026
